Mark Velleca, MD, PhD

Venture Partner

Dr. Mark Velleca was most recently the Chief Executive Officer of Hatteras portfolio company G1 Therapeutics (GTHX), where he took the company public and led the development of its first therapy (COSELA) from IND filing to FDA approval. Previously, he served as Executive Vice President at the Leukemia & Lymphoma Society (LLS). Prior to LLS, Mark was a co-founder and Senior Vice President of CGI Pharmaceuticals, where he managed the company from its inception through clinical trials of multiple drug candidates. After Gilead Sciences acquired CGI, he served as a Senior Advisor to Gilead in R&D Strategy and Corporate Development.

Earlier in his career, Mark was an attending physician at Yale New Haven Hospital and on the faculty of the Yale University School of Medicine.

Currently, Mark is the Chief Executive Officer of StrideBio, a Hatteras portfolio company. He is also Senior Advisor and board member at G1 Therapeutics, board chair at Hatteras portfolio company IMMvention Therapeutix, and board member at Black Diamond Therapeutics. With Hatteras, Mark supports the biopharma portfolio and assists with advising and developing new biopharma companies.

Mark earned an M.D. and Ph.D. from Washington University in St. Louis, and a B.S. from Yale University.